velopment. 30 Furthermore, cognitive dysfunction worsens with increases in AED dosage, 32 higher AED levels, and polytherapy, 1, 21 all of which are common in brain-injured patients. 7 In contrast to patients with epilepsy, however, in whom the adverse cognitive effects of AEDs are offset in part by the beneficial effects of seizure reduction, the risk of seizures in patients with SAH may be low enough that the risks of treatment outweigh the benefits. There are, however, few studies addressing the impact of prophylactic AED use on in-hospital complications, and outcome in patients with SAH has not been systematically studied.
The raw data collected in approximately 3500 patients with SAH were used to explore several questions related to AED use : 1) 
Clinical Material and Methods

Patient Population
Data collected in 3552 patients with aneurysmal SAH who were recruited into four randomized, double-blind, placebo-controlled trials to evaluate the usefulness of the drug tirilazad were analyzed (Fig. 1) . 8, 9, 12, 14, 15 These trials were conducted in neurosurgical centers in 21 countries in Europe, Australia, North America, and Africa between 1991 and 1997. Adult patients with ruptured saccular aneurysms were included. Detailed inclusion and exclusion criteria have been published. 12, 14, 15 
Definition of Clinical and Radiological Variables
Neurological grade was classified using the WFNS scale. The patient's BP and body temperature were recorded on admission and on Day 8 post-SAH. Preexisting medical conditions were documented. Prophylactic and therapeutic hemodynamic therapy (hemodilution, induced hypertension, and hypervolemia) for symptomatic vasospasm after Day 2 was recorded. Data on in-hospital complications such as neurological worsening, cerebral infarction and edema, hydrocephalus, and pulmonary edema were collected. Symptomatic vasospasm was defined using clinical criteria and included the following: 1) symptoms between Days 5 and 12 after SAH (worsening headache, stiff neck, and/or low-grade fever; insidious onset of confusion and/ or decline in level of consciousness; and focal deficit); 2) a head CT scan excluding other causes of worsening; and 3) no other identifiable cause of neurological worsening. Neurological worsening was defined as a decrease of two or more points in the modified GCS score or an increase of two or more points in the motor score of the National Institutes of Health Stroke Scale lasting for 8 or more hours. 21 Outcome was graded 3 months post-SAH by using the GOS. Unfavorable outcome was defined as death, vegetative state, or severe disability. All AEDs prescribed during the hospital course were noted, although seizure occurrence was not recorded.
Radiographic data included grading of the amount of subarachnoid blood on the initial CT scan as none, diffuse or localized thin SAH, or diffuse or localized thick SAH. The presence of hydrocephalus, intraventricular hemorrhage, intracerebral hemorrhage, or vasospasm on admission angiograms was documented. The location and size of the ruptured aneurysm was classified as previously described. [17] [18] [19] 
Statistical Analysis
First, the likelihood ratio tests in a random-effect logistic regression were used to examine whether AED use varied by study country and center. The extent of variation in AED use was described using an intraclass correlation coefficient. The intraclass correlation coefficient is equal to 1 when the use of AEDs is fully determined by a study center (all patients in some study centers used AEDs, but no patients in the other centers used these drugs) whereas it is equal to 0 when the variation by centers is simply due to chance. Second, we explored other predictors of AED use with a conditional logistic regression model in which the study center was the matching set, and in which only patients within the same study center were compared with each other; thus we controlled for confounding due to variation between study centers. Third, we examined the effects of AED use on in-hospital complications and 3-month outcome by using conditional logistic regressions, which, with the same methods described earlier, controlled for confounding data related to the study center. We controlled for study center because it is possible that outcomes may differ between centers due to variations in the patients' condition on admission, the population served, and various aspects of medical management. Finally, we examined differential effects on the 3-month outcome of AED use by disease severity at admission in the framework of a conditional logistic regression model. A probability value of less than 0.05 was considered statistically significant.
Results
Admission Characteristics of the Study Population
The mean age of the 3552 patients was 52 Ϯ 13 years (mean Ϯ SD) and 83% were female. Their clinical conditions were predominately in good grades (36% of patients were categorized in WFNS Grade I, 29% in Grade II, 12% in Grade III, 10% in Grade IV, and 13% in Grade V). The mean GCS score on admission was 11.9 Ϯ 4 (mean Ϯ SD). Thick SAH was observed on admission CT scans in 66% and intraventricular and intracerebral blood in 45 and 23%, respectively. The ruptured aneurysm was 12 mm or less in diameter in 74% of cases. Overall, 90% of patients underwent surgery to clip the ruptured aneurysm at a median of 29 hours (interquartile range 19-48 hours) after the ictus.
Prescribing Pattern for AEDs
Sixty-five percent of patients enrolled in the four clinical trials were given a prescription for at least one AED (Table 1). Phenytoin was the most frequently prescribed drug (52.8%), followed by phenobarbital (18.7%), and only 2.3% of patients received carbamazepine. Concomitant use of two AEDs in an individual patient was found in 8%, and three AEDs were prescribed in only five patients (0.1%). Phenytoin and phenobarbital were less likely to be used simultaneously (OR 0.49, 95% CI 0.41-0.58; p Ͻ 0.0001). Nevertheless, there was no significant association between simultaneous use of phenytoin and carbamazepine (OR 0.72, 95% CI 0.46-1.11; p = 0.13) or between phenobarbital and carbamazepine (OR 1.39, 95% CI 0.84-2.32; p = 0.20).
Predictors of AED Use
Antiepileptic drug treatment varied dramatically according to study country (Fig. 2) . The intraclass correlation coefficient describing the extent of variation in AED use between countries was 0.22 (95% CI 0.20-0.24, 2 = 1594; p Ͻ 0.001). Seven of the 21 study countries enrolled more than 100 patients each, and these groups amounted to 87% of all patients. The rate of AED use varied from 7 to 93% of cases, with a greater than 50% prevalence rate in Australia, Canada, Italy, and the US. In contrast, the intraclass correlation coefficient describing the extent of variation across individual study centers was 0.66 (95% CI 0.62-0.70, 2 = 2184; p Ͻ 0.001), from which we inferred that the use of AEDs was mainly determined by study center and therefore by the treating physician. In other words, even physicians in the same country had different patterns for prescribing AEDs in patients with SAH. Physicians in 15 study centers did not prescribe AEDs at all to the 170 patients enrolled in the trials; in 86 centers, physicians sometimes prescribed these drugs to their 2200 patients; and the remaining physicians in 61 centers always prescribed AEDs to their 1181 patients. Demographic and clinical data for patients enrolled in the four clinical trials are given in Table 2 .
After controlling for variation across study center, which was the most important determinant of AED use, we explored other demographic and clinical characteristics as predictors of AED use; for those investigations we used conditional logistic regression ( 
Primary Outcome and AED Use
Patients treated with AEDs (33%) had a higher rate of unfavorable GOS scores than patients who did not receive AED treatment (26%, Table 2 ). The odds of having an unfavorable outcome was significantly higher in patients treated with AEDs relative to those who were not, after adjustment for study center, WFNS grade, age, and systolic BP on admission (OR 1.56, 95% CI 1.16-2.10; p = 0.003). A sensitivity analysis was conducted by excluding 191 patients who died within the 1st week after SAH. This was done to exclude the possibility of selection bias that might occur if it is assumed that early death indicates severity of disease. The adjusted OR of unfavorable outcome was 1.83 (95% CI 1.33-2.51) for AED treatment.
The detrimental effect of AEDs on 3-month outcome existed among patients in WFNS Grades I to III and in Grades IV and V, demonstrating a lack of disease severity-specific interaction (Table 4) . No significant interaction was observed between age and AED treatment.
There were marginally significant interactions between AED use and thickness of SAH (p = 0.057) and between AED use and intraparenchymal blood on CT scans (p = 0.05). The detrimental effect of AED on outcome was stronger among patients with diffuse thick SAH and among patients without intraparenchymal bleeding.
In-Hospital Complications and AED Use
The percentages of all in-hospital complications examined were higher in patients treated with AEDs than in those without AED use (Table 4) . After adjustment for study center, WFNS grade, age, and systolic BP on admission, AED use was significantly associated with increased odds of clinical vasospasm (odds increase 87%; p Ͻ 0.001) and neurological worsening (odds increase 61%; p Ͻ 0.001). The odds of having cerebral infarction (p = 0.04) and elevated temperature at Day 8 of hospitalization (p = 0.03) were moderately but significantly increased in patients treated with AEDs. There were no significant differences in hydrocephalus, lung edema, brain edema, and use of cerebral angioplasty between the two groups.
Discussion
The key new findings of this study were that two of three patients admitted with acute aneurysmal SAH to neurosurgical centers throughout the world between 1991 and 1997 received AED treatment. Dilantin was the most common single AED used, followed by phenobarbital monotherapy. Antiepileptic drug treatment was determined predominately by the individual treating physician and varied greatly among centers and countries worldwide. These prescribing patterns are of substantial interest in the context of the main finding of this analysis, which was that the use of AEDs was significantly associated with neurological worsening, symptomatic vasospasm, cerebral infarction, fever 8 days after SAH, and poor outcome at 3 months posthemorrhage.
The prophylactic use of AEDs in patients with SAH was introduced after early investigators reported seizure frequencies of 20 to 30%, mostly associated with the initial hemorrhage or following aneurysm rebleeding. 5, 10, 28 However, the risk of early seizures in patients with SAH is currently estimated to be 5 to 8%. 2, 3, 16 The reason for the decline is unknown, but may be related to different diagnostic criteria or to changes in treatment modalities. Administration of AEDs would seem warranted in at least some patients, for example in those with the following conditions: extensive cortical injury, unsecured ruptured aneurysms, increased intracranial pressure, impaired cerebral hemodynamics, and those in whom a seizure might worsen longterm outcome by producing cerebral metabolic stress, changes in BP, and brain swelling. Butzkueven et al. 4 reported that seizures at onset of SAH were independently associated with poor outcome. Nevertheless, they did not consider all prognostic factors for outcome in their multivariate analysis. 11 In another study it was reported that seizures at onset of SAH predict a significant neurological deficit. 16 On the other hand, in other reports it has been suggested that early seizures do not have a significant impact on outcome but rather are a marker of brain injury severity. 10, 28 Several authors reported that prophylactic postoperative AED treatment had no effect on the interval between injury and first seizure or the frequency of early seizures. 26, 37 In addition, the occurrence of perioperative seizures had no influence on the development of chronic epilepsy. 31 Most early seizures occurred at the onset of aneurysmal bleeding in the prehospital setting, 16 when treatment was not available and abnormal movements such as tonic posturing may have been misinterpreted as seizure activity. Therefore, these data in conjunction with our results call into question the current practice of prescribing prophylactic AEDs in two thirds of all patients with SAH.
Antiepileptic drug use in this database was associated with worse outcome at 3 months. This association was independent of admission characteristics such as neurologi-cal grade and variations in treatment modalities among centers. We did not identify a patient subgroup experiencing disproportionate impairment or actually benefiting from prophylactic AED treatment. There was a more favorable overall outcome in patients with SAH who were not treated with AEDs, despite the likelihood that seizures may have occurred with relatively higher frequency in these patients. There are no randomized studies in which the risks and benefits of early prophylactic AED treatment in patients with SAH have been investigated, but in trials conducted in patients with head injury it was reported that AEDs did not reduce early or late seizure incidence or affect mortality rates. 37 The reasons for the association between AEDs and poor outcome are a matter of speculation. Antiepileptic drugs reduce neuronal irritability, which may result in altered
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Outcome in patients with SAH treated with AEDs † These values given as means Ϯ SDs. ‡ Unfavorable outcome was defined as death, vegetative state, or severe disability on the GOS. § Neurological worsening was defined as a greater than two-point decrease in the modified GCS score or a greater than two-point increase in the motor score of the National Institutes of Health Stroke Scale lasting 8 or more hours. synaptic growth and connectivity, which in turn may be important in neurological recovery. 22 Most AEDs impair cognitive function, 6 both in healthy volunteers and in patients with brain impairment. 23, 24, 34 Dilantin and phenobarbital were found to impair recovery from brain injury in animal studies. 7 Many AEDs enhance ␥-aminobutyric acidergic inhibition or block glutamate-mediated excitation and are known to cause widespread and dose-dependent apoptotic neurodegeneration in the developing rat brain, 18 even when given only for several hours. 27 Studies performed in animal models identified potential neuroprotective effects of AEDs when given at the time of the ischemic event, 25 but this effect was only present in vitro when the ischemic insult was of short duration. 36 On the other hand, Goldstein 6 reported that phenytoin worsens cerebral ischemia. Compared with controls, children exposed in utero to AEDs had a reduced full-scale IQ score 29, 33 and impaired neurobehavioral development. 30 Cerebral vasospasm after SAH is a combination of prolonged contraction and vessel remodeling leading to cerebral ischemia, clinical deterioration, and infarction. 19 Investigators have described apoptosis of cerebral endothelial cells 38 in addition to smooth-muscle cell necrosis 37 in animal models, providing one possible explanation for how AEDs could aggravate cerebral vasospasm. Use of AEDs was also associated with an increased risk of fever 8 days after admission. Although adverse reactions to AEDs were serious enough to discontinue therapy in 10 to 18% 20, 26 of patients, fever itself is strongly associated with poor functional and cognitive outcome.
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Conclusions
The limitations of this analysis include lack of information on seizure occurrence and frequency among patients who were treated or not treated with AEDs. However, if we use current estimates of 5 to 8% of early seizures in patients with SAH, the adjusted OR would still be 1.44 and 1.37, respectively, for an unfavorable GOS score in patients treated with AEDs. Even in this worst-case scenario, there would be no beneficial effect of prophylactic AED treatment. Within the study, AEDs were used in two thirds of all patients with SAH, and based on current practices, these drugs would most commonly have been administered prophylactically beginning at the time of admission. We also do not have data on the duration or intensity of AED expo- sure; the database was not designed primarily to evaluate the influence of AED treatment on outcome in patients with SAH. Patients treated with AEDs may be sicker, and thus the observed detrimental effects could simply have been due to selection bias. After adjustment for study center, neurological grade, age, and systolic BP on admission, however, we found that AED users still had a higher risk of unfavorable outcome. We cannot rule out unmeasured differences within the same study center between the two groups; such selection bias can only be accounted for in randomized controlled studies. Despite these shortcomings, the strong associations of multiple adverse events with use of AEDs in patients with aneurysmal SAH are of great interest, particularly in view of the continuing devastating overall effects of SAH. Furthermore, if no beneficial effect of prophylactic AEDs was demonstrated after adjustment for seizure occurrence (based on current estimated risk), then the use thereof becomes of questionable benefit. These results support the need for prospective randomized studies.
